Add BrightSurf on Google Email

Wyss Institute at Harvard University announces appointment of Natalie Artzi, Ph.D., to Associate Institute Director

Dr. Natalie Artzi joins the Wyss Institute as Associate Institute Director, working closely with Don Ingber to shape strategic direction and advance research and translation efforts. She leads a world-class research program focused on developing tissue- and cell-responsive nanostructures for disease tracking and treatment.

Adenosine phosphate signaling unleashes antitumor immunity and enhances immunotherapy efficacy in melanoma

Researchers identified five adenosine phosphate signaling subtypes in melanoma, associated with immune activation and improved response to anti-PD-1/PD-L1 therapy. The Adenosine Phosphate Signaling Model predicts prognosis and immunotherapy outcomes, offering new biomarker and therapeutic strategies for solid tumors.

Common antidepressants could help the immune system fight cancer, UCLA study finds

A UCLA study found that selective serotonin reuptake inhibitors (SSRIs) can significantly enhance the ability of T cells to fight cancer and suppress tumor growth across various cancer types in mouse and human tumor models. SSRIs increased access to serotonin signals, making killer T cells happier and more effective at killing cancer c...

Oxidative stress and antigen processing and presentation: A novel perspective for precision immunotherapy

A new review article reveals the dynamic mechanisms of ROS regulating antigen processing and presentation, proposing combined immunotherapy strategies based on redox homeostasis regulation. Targeting redox homeostasis is a promising direction for enhancing tumor immunotherapy efficacy.

A new CAR-T-cell therapy that tricks the tumor could increase treatment efficiency in B-cell Acute Lymphoblastic Leukemia

Researchers have developed a new approach to improve CAR-T cell therapy effectiveness in treating B-cell Acute Lymphoblastic Leukemia. By creating a TIM-3 decoy, they aim to prevent the tumor from turning off the CAR-T cells, leading to improved anti-leukaemia effectiveness and long-term persistence.

SourceJosep Carreras Leukaemia Research Institute·JournalBlood·TypeExperimental study·DateMar 21, 2025

Radiation plus combination immunotherapy may help preserve bladder in some patients with muscle-invasive bladder cancer

Researchers found that radiation combined with immune checkpoint inhibitors durvalumab and tremelimumab resulted in durable responses allowing for bladder preservation in localized MIBC patients. The study showed a high efficacy rate of 93% complete response rate, with 84% overall survival rate after two years.

SourceAmerican Association for Cancer Research·JournalClinical Cancer Research·DateFeb 18, 2025

New immune-probing technique could boost treatment discovery

Researchers at Osaka University developed a new technique called single-cell suppressive profiling of regulatory T cells (scSPOT) that can pinpoint the effects of Tregs on all other immune cells. The study found that Tregs most strongly affect CD8-EM T cells, which play a key role in fighting cancer and infections.

SourceOsaka University·JournalNature Communications·TypeExperimental study·DateFeb 12, 2025

Eating gradually increasing doses of store-bought peanut butter enables children with high-threshold allergy to safely consume peanuts

A new study led by researchers at Mount Sinai Hospital found that children with high-threshold peanut allergy can be treated with a safe and effective approach, allowing them to tolerate larger doses of peanut butter. The treatment involves gradually increasing doses over 18 months, resulting in sustained unresponsiveness to peanuts fo...

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNEJM Evidence·TypeExperimental study·DateFeb 10, 2025

Researchers develop a device that replicates tumours to study the efficacy of immunotherapy treatments

The Micro Immune Response On chip (MIRO) replicates tumours and their environment, allowing researchers to study the efficacy of immunotherapy treatments. This technology has been tested with breast cancer samples and shows promise in understanding how the immune system interacts with tumours.

SourceInstitute for Bioengineering of Catalonia (IBEC)·JournalNature Communications·TypeExperimental study·DateFeb 6, 2025

Anti-correlation between KLRG1 and PD-1 in tumor CD8 T cells

A new study published in Oncotarget discovered an anti-correlation between PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells. This finding suggests the potential for combination therapy to enhance cancer treatment by targeting both markers simultaneously, which could lead to more significant and long-lasting benefits.

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateJan 21, 2025

Your immune cells are what they eat

Researchers at Salk Institute establish a novel framework for the relationship between nutrition and cell identity. They found that a nutritional switch from acetate to citrate plays a key role in determining T cell fates, shifting them from active effector cells to exhausted cells.

SourceSalk Institute·JournalScience·DateDec 12, 2024

Therapeutic potential of a novel mixture of mRNA in nanoparticles overcomes tumor progression

A novel mixture of mRNA in nanoparticles has been developed to protect therapeutic mRNA against degradation, improving its overall efficacy. The therapy stimulates the immune system to recognize and eliminate cancer cells while limiting detrimental side effects, also leading to immunological memory that protects against tumor rechallenge.

SourceVrije Universiteit Brussel·JournalNature Communications·DateDec 9, 2024

Global clinical trial shows improved survival rates for common childhood leukemia

A global clinical trial has shown a significant improvement in disease-free survival rates for children with B-cell acute lymphoblastic leukemia (B-ALL) by combining standard chemotherapy with blinatumomab, an immunotherapy. The study found improved survival rates of up to 97.5% after three years, compared to 90% with chemotherapy alone.

SourceThe Hospital for Sick Children·JournalNew England Journal of Medicine·DateDec 7, 2024

Opioids interfere with cancer immunotherapy but these drugs could help

New research from the University of Pittsburgh found that opioids can suppress the immune system and reduce the effectiveness of immunotherapy for head and neck cancer. However, peripherally restricted OPRM1 antagonists (PAMORAs) may block opioid-induced immunosuppression and improve response rates to immune checkpoint inhibitor therapy.

SourceUniversity of Pittsburgh·JournalJournal for ImmunoTherapy of Cancer·DateDec 5, 2024

Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies

EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating detectable virus within 24 hours. It also recruits naturally occurring antibodies to fight the virus, reducing viral loads and protecting against lung damage.

SourcePurdue University·JournalProceedings of the National Academy of Sciences·DateNov 19, 2024

Wyss Institute’s iNodes team receives ARPA-H Sprint for Women’s Health award to advance the first implantable immune organs to treat ovarian cancer

The Wyss Institute's iNodes team has been awarded an ARPA-H Sprint for Women's Health to develop implantable immune organs for treating ovarian cancer. The iNodes concept is based on the formation of lymphoid organs in tumors, which can be reprogrammed to attack cancer cells and retain a long-term immune memory.

CNIO researchers propose a new treatment for brain metastasis based on immunotherapy

Researchers at CNIO propose a new treatment for brain metastasis by targeting pro-tumour astrocytes with immunotherapy. They identified TIMP1 as a biomarker to predict when immunotherapy is effective, and a clinical trial is underway to test the therapeutic efficacy of silibinin inhibition.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalCancer Discovery·TypeExperimental study·DateOct 2, 2024

Immunotherapy for gum disease? Study in mice shows promise

A new study published in PNAS suggests that delivering microparticles containing CCL2 directly to the gums can inhibit bone loss and speed up bone repair in a mouse model of periodontal disease. The therapy modulates the immune response, shifting macrophages from inflammatory M1 type to anti-inflammatory M2 type.

SourceUniversity of Pittsburgh·JournalProceedings of the National Academy of Sciences·DateSep 30, 2024

AI unlocks new path to personalized cancer treatments

Researchers at Auburn University have developed a novel approach integrating artificial intelligence with molecular dynamics simulations and network analysis to enhance the prediction of binding sites on the PD-L1 protein. Their findings could improve immunotherapies like pembrolizumab, revolutionizing cancer treatment.

SourceAuburn University Department of Physics·JournalJournal of the American Chemical Society·TypeExperimental study·DateSep 5, 2024